IRF5 Inhibitor

About Totus Medicines

Totus Medicines is a private, preclinical-to-clinical stage biotech founded in 2019 and headquartered in Cambridge, Massachusetts. The company leverages its proprietary OmniDEL platform—which combines ultra-high-throughput cell-based screening of covalent libraries with AI/ML-powered drug design—to develop oral covalent inhibitors against validated but poorly drugged or previously undruggable targets. Its lead asset, TOS-358, is a covalent PI3Kα inhibitor in Phase 1 trials for oncology, with a discovery program targeting IRF5 in immunology and inflammation. Totus represents a convergence of covalent chemistry, functional genomics, and machine learning aiming to unlock new therapeutic modalities.

About HotSpot Therapeutics

HotSpot Therapeutics, founded in 2017 and based in Boston, is a private, preclinical-stage biotech developing a new class of allosteric drugs. The company's proprietary Smart Allostery™ platform integrates structural biology, pharmacology, chemistry, and AI to systematically drug natural regulatory hotspots on proteins. This approach aims to create highly selective and potentially safer therapeutics for challenging targets in oncology and autoimmunity, representing a significant departure from traditional drug discovery paradigms.

Therapeutic Areas

Other Autoimmune & Inflammatory diseases Drugs